Phase 3 N=1,056 Effect of Sulodexide in Early Diabetic Nephropathy
Diabetic Nephropathy
Primary: Number of Subjects With Conversion From Microalbuminuria to Normoalbuminuria — 39; 30 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=369 A Study In Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Median Percent Change From Baseline to Week 6 in LDL-c in FDC and RSG Monotherapy — -39.9; 5.4 Percent change in LDL-c — p=<0.0001
Phase 3 N=149 A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis
Genital Psoriasis · Psoriasis
Primary: Number of Participants Achieving Static Physician Global Assessment (sPGA) of Genitalia (0,1) — 6; 55 Participants — p=<0.001
Phase 3 N=42 Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis
Cystitis, Interstitial
Primary: IC/BPS Symptoms Change With Overall Global Response Assessment (GRA) — 2; 1 Participants
Phase 3 N=653 Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD
COPD
Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 — 0.0961; 0.0886; -0.0075 liters — p=<0.0001
Phase 3 N=856 A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma
Uncontrolled Asthma
Primary: Annualised Asthma Exacerbation Rate (AAER) up to Week 52 — 0.80; 0.95; 0.87; 0.77 Events/year — p=0.4656
Phase 3 N=430 A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Subjects Meeting the American College of Rheumatology 20 % Response Criteria (ACR20) at Week 24 — 23.9; 54.8 percentage of participants — p=<0.001
Phase 3 N=77 Decadron as Adjuvant in Femoral Nerve Blocks in Knee Arthroscopy
Knee Injury
Primary: Intra-operative and Post-operative Opioid Consumption — 2; 2; 3 doses
Phase 3 N=1 CU Programme of Idarucizumab for Japanese Patients
Hemorrhage
Primary: Percentage of Subjects With Drug-related Adverse Events — 0.0 Percentage of participants
Phase 3 N=117 Aim to Reduce Movements in Tardive Dyskinesia
Tardive Dyskinesia
Primary: Change in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using Mixed Model Repeated Measures (MMRM) Analysis — -3.0; -1.6 units…
Phase 3 N=495 A Study in Adult Patients With Major Depressive Disorder
Depressive Disorder, Major
Primary: Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) at Week 10 — -13.30; -9.82 units on a scale — p=<0.001
Phase 3 N=955 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)
Varicella · Measles · Mumps
Primary: Percentage of Participants Meeting Antibody Response Rate Criteria to Measles, Mumps, Rubella, and Varicella — 97.4; 96.3; 96.7; 98.6 Percentage of Participants
Phase 3 N=46 Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study
Psoriasis
Primary: Percentage of Participants Achieving a Satisfactory Response at Week 16 Based on Investigator Assessment — 33.3; 52.5; 50.0 percentage of participants
Phase 3 N=343 Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures
Epilepsy
Primary: Change in Partial Onset Seizure (POS) Frequency Per 28 Days From Baseline to the Maintenance Period — -1.55; -3.05 Seizures per 28 days — p==0.0003
Phase 3 N=131 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
Primary Cutaneous Anaplastic Large Cell Lymphoma · Mycosis Fungoides · Cutaneous T-Cell Lymphoma
Primary: Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4) — 54.7; 12.5 percentage of participants — p=<0.001